Thymosin Beta 4 Dosage Calculation for Concentration Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for administering thymosin beta 4 face challenges in maintaining a desired concentration, leading to inefficient treatment and potential side effects due to fluctuating drug levels, requiring frequent re-dosing and resulting in waste or inadequate dosing.

Innovation Solution

A method using the formula C=(A)D·t−B to determine the dosage (D) of thymosin beta 4, where C is the desired concentration, A is approximately 30 to 38, and B is about 0.5 to 1, to achieve and maintain a predetermined concentration in the body, minimizing drug waste and optimizing treatment efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If a high initial dosage of thymosin beta 4 is administered to achieve desired concentration quickly, then the initial concentration is sufficient, but the concentration rapidly decreases requiring frequent re-dosing

Engineering Contradiction:
Improvethymosin beta 4 concentrationVSAvoidduration of effective concentration
Core Design Contradiction:
Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent segments the total dosage into multiple smaller administrations spaced at specific time intervals rather than giving one large dose. This is achieved by calculating optimal dosing schedules that divide the total required thymosin beta 4 into discrete administrations, maintaining concentration within the therapeutic window without excessive peaks or troughs

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent implements periodic administration of thymosin beta 4 at calculated time intervals to maintain steady therapeutic concentrations. The dosing schedule is determined by the formula that predicts concentration over time, allowing periodic reinforcement of the drug in the system to sustain effective levels without accumulation or depletion

Inventive Principle:
Principle #19Periodic action

2Quantity of substance

If frequent re-dosing is administered to maintain concentration, then the desired concentration is maintained, but treatment efficiency decreases and total drug administration increases

Engineering Contradiction:
Improvethymosin beta 4 concentrationVSAvoidtreatment efficiency
Core Design Contradiction:
Quantity of substanceVSProductivity

Solution Approach 1:

The patent uses a mathematical model that incorporates feedback about drug concentration dynamics to optimize dosing. The formula C=(A)D·t−B allows calculation of the optimal dosing schedule by considering the predicted concentration at any time point, enabling practitioners to determine the minimum necessary dosing frequency to maintain therapeutic levels without excessive administrations

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The patent changes the timing parameter of drug administration from fixed intervals to optimized intervals based on the pharmacokinetic model. By adjusting the time parameter t in the concentration formula, the dosing schedule is optimized to maintain concentration with fewer administrations, improving treatment efficiency while maintaining therapeutic efficacy

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If high initial concentration is achieved, then therapeutic effect is maximized initially, but fluctuating concentrations cause unpredictable effects and potential dangers

Engineering Contradiction:
Improvethymosin beta 4 concentrationVSAvoidconcentration predictability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent employs a self-regulating dosing system where the mathematical model automatically accounts for the drug's pharmacokinetics. The formula C=(A)D·t−B inherently predicts concentration decay and guides subsequent dosing to maintain stability, creating a self-correcting system that automatically adjusts for the drug's natural elimination rate without requiring manual intervention to prevent fluctuations

Inventive Principle:
Principle #25Self-service

Data Source

PatentUS9504730B2Method of achieving a thymosin beta 4 concentration in a human patient
Publication Date: 2016.11.29 REGENERX BIOPHARMACEUTICALS INC

AI summary

The present invention provides embodiments which involve methods of providing a predetermined concentration of thymosin beta 4 (TB4) at a predetermined time, t, in a body portion of a live human patient. The methods can include determining a thymosin beta 4 treatment dosage (D) using Formula I: C=(A)D·t−B, wherein C is the predetermined concentration at time t, in ng/mL, D is the dosage of thymosin beta 4 administered in mg, t is the time elapsed after administration of dosage D in hours, A is about 30 to about 38, and B is about 0.5 to about 1; and administering the dosage (D) of thymosin beta 4 to the patient. Formula I may be, for example,C=(35.6)D·t−0.754  (Formula II).